# Extended-release Guanfacine Hydrochloride in Children/Adolescents With Attention-deficit/Hyperactivity

> **NCT03662763** · PHASE3 · COMPLETED · sponsor: **Maastricht University Medical Center** · enrollment: 12 (actual)

## Conditions studied

- Attention Deficit Disorder

## Interventions

- **DRUG:** Extended-release Guanfacine Hydrochloride (SPD503)
- **DRUG:** Placebo oral capsule

## Key facts

- **NCT ID:** NCT03662763
- **Lead sponsor:** Maastricht University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2013-08
- **Final completion:** 2013-12
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2018-09-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03662763

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03662763, "Extended-release Guanfacine Hydrochloride in Children/Adolescents With Attention-deficit/Hyperactivity". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03662763. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*